GeoVax Points to Victories in Fight Against AIDS

GeoVax Points to Victories in Fight Against AIDS

By: Dylan Sikes – News

Monday, December 2, 2019

It is World AIDS Day, a somber reminder of the fight against this dreaded disease, how much more remains to be done. 

Atlanta-based GeoVax Labs Inc. (OTC:GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, observed the date as  a global initiative to raise awareness, fight prejudice, and improve education about HIV and AIDS.

According to CEO David Dodd, “The U.S. federal theme for the 2019 World AIDS Day observance is Ending the HIV/AIDS Epidemic: Community by Community.  

“GeoVax is committed to an AIDS-free generation through vaccine and immunotherapy development, and today we would like to highlight our continuing contributions to this effort, as well as recognize the work being done by our partners and collaborators. Defeating HIV/AIDS will require a multi-pronged approach, encompassing multiple strategies for both prevention and treatment of the disease, and we are pleased to be contributing in multiple areas.

“Our preventive HIV vaccine candidate (GOVX-B11) was originally conceived under the leadership of our scientific founder, Dr. Harriet Robinson, in collaboration with the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and Emory University.” 

Shares in the company gathered 7.7%, to seven-100ths of a cent, on just over a million shares.

Copyright © 2019 All rights reserved. Republication or redistribution of's content is expressly prohibited without the prior written consent of shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon

Other Penny Stock Movers

This Merger Candidate Should Start Moving Up
VistaGen Fast-Tracked by FDA for SAD Treatment
Tetra Jumps on Cancer Drug Tests
MacDonald Mines Hikes on New Discoveries

Back to Top